Answers are grounded in this paper and cite their sources.
Erythropoiesis (EPO)-stimulating agents (ESAs) are recommended first-line therapy for symptomatic anemia in lower-risk myelodysplastic syndrome (MDS), reducing transfusion dependence in 40% to 60% of eligible patients.1 Arthralgia and myalgia are recognized side effects of ESAs,1 but evident inflammatory monoarthritis directly attributable to ESA therapy has not, to our knowledge, been previously reported.
No takes yet. Share an insight, caveat, or question.
Ouamer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: